Association between obstructive sleep apnea severity and glymphatic-related DTI-ALPS alterations in newly diagnosed, Drug-Naïve Alzheimer's disease

This study examined whether the severity of obstructive sleep apnea (OSA) is linked to impaired brain waste-clearance in patients newly diagnosed with Alzheimer's disease (AD). The brain's 'glymphatic system' — a network of fluid channels around blood vessels that flushes out toxic proteins like amyloid-beta during sleep — was measured using a specialized MRI technique called DTI-ALPS, which tracks water diffusion in tissue surrounding brain vessels. Researchers enrolled 162 drug-naïve AD patients and 98 healthy controls, giving all participants overnight sleep studies (polysomnography) alongside the MRI scans. They found that in AD patients, worse OSA — measured by apnea-hypopnea index (AHI) and oxygen desaturation index (ODI) — was significantly associated with lower DTI-ALPS scores, meaning more glymphatic dysfunction. Crucially, this relationship was absent in healthy controls, suggesting the brain's vulnerability to sleep-disordered breathing is amplified in AD. Lower ALPS scores also tracked with more fragmented sleep, less REM sleep, and worse performance on standard cognitive tests. The findings support a mechanistic chain in which OSA disrupts the sleep-dependent glymphatic clearance of amyloid and tau, potentially accelerating neurodegeneration specifically in those who already carry AD pathology.

• In AD patients, AHI was inversely correlated with ALPS-index (rho = -0.38, P < 0.001) and ODI was similarly inversely correlated (rho = -0.35, P < 0.001); neither association was significant in healthy controls, suggesting an AD-specific vulnerability.
• Lower ALPS-index values were associated with more fragmented sleep architecture: higher N1 sleep proportion, higher arousal index, and reduced REM sleep percentage — sleep stages critical for glymphatic activity.
• ALPS-index correlated positively with better cognitive scores on MMSE (rho = 0.28, P = 0.001) and MoCA (rho = 0.31, P < 0.001), and negatively with greater impairment on ADAS-Cog (rho = -0.34, P < 0.001), linking glymphatic dysfunction to clinical cognitive severity.
• The study used interaction-term multivariable regression and sensitivity analyses to confirm the OSA–glymphatic dysfunction relationship was specific to the AD group rather than a general consequence of sleep-disordered breathing.
• All AD participants were newly diagnosed and drug-naïve, substantially reducing confounding from disease-modifying or symptomatic AD medications on either sleep architecture or DTI-ALPS measurements.

This was a cross-sectional observational study enrolling 162 newly diagnosed, drug-naïve AD patients and 98 healthy controls at a single center. OSA severity was characterized by full-night polysomnography (PSG), capturing AHI, ODI, sleep staging, arousal index, and REM proportions. Glymphatic function was quantified using the DTI-ALPS index derived from diffusion tensor imaging sequences targeting water diffusivity in the perivascular space of projection and association fibers. Statistical analyses included Spearman correlations, multivariable linear regression with AD-by-OSA interaction terms, and sensitivity analyses to test whether associations were group-specific.

The cross-sectional design precludes causal inference — it is impossible to determine whether OSA-driven glymphatic failure accelerates AD pathology or whether AD neuropathology (e.g., perivascular amyloid deposition) worsens both glymphatic flow and sleep-disordered breathing simultaneously. DTI-ALPS is an indirect, proxy measure of glymphatic function and cannot quantify actual interstitial fluid dynamics or amyloid-beta clearance rates directly. The single-center sample and lack of longitudinal follow-up limit generalizability; future studies should track ALPS-index change after CPAP therapy to establish whether treating OSA restores glymphatic function and slows cognitive decline. Amyloid PET or CSF biomarker data were not reported, so the link between ALPS values and actual amyloid/tau burden remains inferential.

This study extends the OSA-neurodegeneration thread opened by [§109], which explores how OSA-induced inflammatory signaling (via METTL14/JAK2/STAT3) drives systemic tissue injury, by adding a distinct mechanistic arm — glymphatic failure — that may be equally or more directly relevant to AD pathophysiology. It parallels [§96], which documents neurocognitive impairment in elderly veterans with OSA and comorbid COPD, reinforcing that sleep-disordered breathing exerts measurable cognitive costs in aging populations, though the present study isolates glymphatic dysfunction as a putative structural mediator. The work also resonates with [§33] (TREAD trial), which targets Alzheimer's disease through time-restricted eating partly by optimizing metabolic and circadian factors that modulate glymphatic clearance, suggesting complementary interventional angles on the same waste-clearance pathway. Finally, it contextualizes findings from [§110], which examines how intermittent hypoxia from OSA alters loop gain in healthy subjects, by demonstrating that hypoxia-related sleep fragmentation carries neurological consequences that manifest selectively in AD-vulnerable brains rather than in healthy controls.

• Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
  Directly comparable population: older adults with OSA and cognitive comorbidities; provides neurocognitive outcome data against which to benchmark the AD-specific glymphatic findings.
• METTL14 Regulates Adipose Tissue Macrophage Polarization via JAK2 / STAT3 Pathway to Attenuate Obstructive Sleep Apnea‐Related Systemic Inflammation
  Examines a parallel OSA-to-neurodegeneration pathway (METTL14-driven macrophage polarization and inflammation) in the same disease context, allowing readers to weigh inflammatory vs. glymphatic mechanisms as OSA injury routes.
• TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
  TREAD targets Alzheimer's disease via circadian/metabolic optimization that intersects glymphatic clearance rhythms; comparison illuminates whether dietary timing or OSA treatment is the more tractable intervention for restoring waste-clearance.
• Influence of Intermittent Hypoxia on Loop Gain in Healthy Subjects
  Investigates the upstream physiological effect of intermittent hypoxia on loop gain in healthy subjects, providing mechanistic context for why AHI and ODI — the hypoxic burden metrics — drive glymphatic disruption in the present AD cohort.
• Sleep and Performance
  Covers broad sleep-performance relationships; juxtaposing it with this study highlights how OSA's cognitive costs in AD extend beyond generic sleep-quality effects to a specific structural glymphatic impairment mechanism.